Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Dec 12, 2022
- Accession no.
- 0001415889-22-012429
- Filed
- Dec 12, 2022
- Trade date
- Dec 8-9, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $236.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $2.14 | +$21,400 | 10,000 | Direct | |
| Dec 8, 2022 | Common Stock | SSaleDisposed | −928 | $20.94F2 | −$19,432.32 | 9,072 | Direct | |
| Dec 8, 2022 | Common Stock | SSaleDisposed | −2,695 | $21.63F3 | −$58,292.85 | 6,377 | Direct | |
| Dec 8, 2022 | Common Stock | SSaleDisposed | −3,199 | $22.56F4 | −$72,169.44 | 3,178 | Direct | |
| Dec 8, 2022 | Common Stock | SSaleDisposed | −3,178 | $24.08F5 | −$76,526.24 | 0 | Direct | |
| Dec 9, 2022 | Common Stock | MOption exerciseAcquired | +394 | $2.14 | +$843.16 | 394 | Direct | |
| Dec 9, 2022 | Common Stock | SSaleDisposed | −394 | $25.03F6 | −$9,861.82 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 208,030 | Direct | |
| Dec 9, 2022 | Common Stock | MOption exerciseDisposed | −394 | $0.00 | $0 | 207,636 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.235 to $21.22, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.25 to $22.20, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.27 to $22.845, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.43 to $24.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary